Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $127.1K in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Athira Pharma is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO | Mar 03 '26 | Option Exercise | $0.00 | 22,254 | $0 | 63,082 | Mar 05 07:14 PM |
| Litton Mark James | PRESIDENT and CEO | Mar 04 '26 | Sale | $5.37 | 5,156 | $27,688 | 57,926 | Mar 05 07:14 PM |
| Renninger Robert | CHIEF FINANCIAL OFFICER | Mar 03 '26 | Option Exercise | $0.00 | 3,900 | $0 | 16,757 | Mar 05 07:10 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.